+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter phase II study of sequential hormonotherapy with Anastrozl/Exemestane in metastatic breast disease Preliminary data of goim 2107 Study



Multicenter phase II study of sequential hormonotherapy with Anastrozl/Exemestane in metastatic breast disease Preliminary data of goim 2107 Study



EJC Supplements 1(5): S139




(PDF emailed within 1 workday: $29.90)

Accession: 035349870

Download citation: RISBibTeXText


Related references

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. British Journal of Cancer 92(9): 1621-1625, 2005

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Annals of Oncology 15(2): 211-217, 2004

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. Journal of Clinical Oncology 17(11): 3418-3425, 1999

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology 14(9): 1391-1398, 2003

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Research and Treatment 116(3): 501-508, 2008

Exemestane (Exe) as primary treatment in hormonosensible early breast cancer of the elderly: Preliminary results of a phase II multicenter open Italian study. Journal of Clinical Oncology 24(18_suppl): 10689-10689, 2016

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology 17 Suppl 7: Vii73-7, 2006

Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clinical Breast Cancer 6 Suppl 2: S41-S44, 2006

Metastatic breast carcinoma: sequential hormonotherapy with tamoxifen and medroxy-progesterone acetate. preliminary results. Bulletin du Cancer 69(2): 170-171, 1982

Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases. Zhonghua Yi Xue Za Zhi 83(3): 188-190, 2003

Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Future Oncology 10(5): 725-733, 2014

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM). Anti-Cancer Drugs 8(10): 943-948, 1998

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: A phase II study of the Southern Italy Oncology Group (GOIM). Anti Cancer Drugs 8(10): 943-948, 1997

Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study. Clinical Breast Cancer 10(4): 313-317, 2010

Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clinical Breast Cancer 1 Suppl 1: S15-S18, 2002